EAHP 2012 Report – The EAHP Survey 2010 Preview
by Zara Qadir – Five years of evolution in Hospital Pharmacy. The 40th EAHP meeting provided an opportunity for Tajda Miharija-Gala and Juraj Sykora, Directors of Professional Development,… read more.
by Zara Qadir – Five years of evolution in Hospital Pharmacy. The 40th EAHP meeting provided an opportunity for Tajda Miharija-Gala and Juraj Sykora, Directors of Professional Development,… read more.
by Zara Qadir reporting on the presentation by Yechiel Hekster (pictured), Professor of Clinical Pharmacy, and a member of The Netherlands Medicines Evaluation Board.
by Bruce Sylvester taken from the New England Journal of Medicine (NEJM) Vismodegib (Erivedge), a new skin cancer drug for advanced basal cell carcinoma, was called “the greatest… read more.
by Bruce Sylvester – In a randomized Phase II study presented at ASCO, investigators reported that 6 months of treatment with the targeted drug abiraterone (Zytiga) when added… read more.
by Bruce Sylvester – Investigators from a Phase III trial reported at ASCO that chemotherapy-induced nausea and vomiting (CINV) which is unresponsive to conventional treatments reponds to olanzapine… read more.
by Bruce Sylvester – Results from an expanded Phase IB trial presented at ASCO suggest that combination therapy with two investigational and targeted drugs, BRAF inhibitor dabrafenib and… read more.
by Bruce Sylvester – Investigators reported at ASCO that relapsed follicular lymphoma patinets treated with combination lenalidomide (Revlimid) and rituximab (Rituxan) achieved a higher percentage of overall response… read more.
by Bruce Sylvester – In a phase I study presented at ASCO, researchers reported that crizotinib (Xalkori) stalled tumor growth and, in some cases, eradicated all signs of… read more.
by Gary Finnegan – World Health Matters (Germany) – An interdisciplinary care model for breast cancer management has grown in popularity in recent years and evidence suggests the… read more.
The antidepressant duloxetine (Cymbalta ®) can effectively treat chemotherapy-induced neuropathy in some patients , researchers reported on July 3, 2012 at the American Society of Clinical Oncology Annual… read more.
by Bruce Sylvester – Emerging uses of FDA Approved Drugs – Treatment with pazopanib nearly tripled progression-free survival (PFS), compared with placebo, among patients with metastatic soft-tissue sarcoma… read more.
by Bruce Sylvester – Emerging uses of FDA Approved Drugs – A hormone-depleting drug approved in 2011 for the treatment of metastatic prostate cancer appears to help eliminate… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.